<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03719326</url>
  </required_header>
  <id_info>
    <org_study_id>AB928CSP0002</org_study_id>
    <nct_id>NCT03719326</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies</brief_title>
  <official_title>A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast or Gynecologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arcus Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Infinity Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Arcus Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/1b, open-label, dose-escalation, and dose-expansion study to evaluate the
      safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of
      AB928 in combination with pegylated liposomal doxorubicin (PLD) with or without IPI-549 in
      participants with advanced metastatic triple-negative breast cancer (TNBC) or ovarian cancer,
      and AB928 in combination with nanoparticle albumin-bound-paclitaxel (NP) in participants with
      advanced metastatic TNBC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the dose escalation phase, the following will be assessed:

        -  Arm A: escalating doses of AB928 in combination with PLD at standard doses will be
           assessed in participants with advanced metastatic triple-negative breast cancer or
           ovarian cancer. Eligible participants will receive oral administration of AB928 as well
           as intravenous (IV) infusion of PLD. The recommended dose (RDE) for expansion Arms 1 and
           2 and escalation Arm C will be determined upon completion of this dose escalation arm.

        -  Arm B: escalating doses of AB928 in combination with the NP at standard doses will also
           be assessed in participants with advanced metastatic TNBC. Eligible participants will
           receive oral administration of AB928 as well as NP infusion. The RDE of AB928 will be
           determined upon completion of this dose escalation arm.

        -  Arm C: escalating doses of IPI-549 in combination with the RDE of AB928 (from Arm A) and
           PLD at standard doses will be assessed in participants with advanced metastatic TNBC or
           ovarian cancer. Eligible participants will receive oral administration of both AB928 and
           IPI-549 as well as IV infusion of PLD. The RDE of IPI-549 for expansion Arm 4 will be
           determined upon completion of this dose escalation arm.

      In the dose expansion phase, the following will be assessed:

        -  Arms 1 and 2: AB928 at the RDE in combination with PLD at standard doses may be assessed
           in participants with advanced metastatic TNBC or ovarian cancer.

        -  Arm 3: AB928 at the RDE in combination with NP at standard doses may be assessed in
           participants with advanced metastatic TNBC.

        -  Arm 4: AB928 and IPI-549 at the RDE in combination with PLD at standard doses may be
           assessed in participants with advanced metastatic TNBC.

      Overall duration of treatment will depend on how well the treatment is tolerated. Treatment
      may continue until unacceptable toxicity or progressive disease or other reasons specified in
      the protocol.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2018</start_date>
  <completion_date type="Anticipated">July 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>3+3 dose escalation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>From first dose date to 30 days after the last dose (Approximately 1 year)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicities (DLTs) during the dose escalation phase</measure>
    <time_frame>From first dose date to 28 days after the first dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of AB928</measure>
    <time_frame>Recorded at baseline (prior to first dose), during the first 4 cycles of treatment (4 months) and at the end of treatment (i.e. in total approximately 5 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of IPI-549</measure>
    <time_frame>Recorded at baseline (prior to first dose), during the first 4 cycles of treatment (4 months) and at the end of treatment (i.e. in total approximately 5 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with a best overall response of Complete Response (CR) or Partial Response (PR), as determined by Investigator according to Response Evaluation in Solid Tumors (RECIST) v 1.1</measure>
    <time_frame>From study enrollment until participation discontinuation, first occurrence of progressive disease or death from any cause, whichever occurs first (approximately 3-5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with Disease Control (complete response, partial response, or stable disease) for &gt; 6 months as determined by RECIST v1.1</measure>
    <time_frame>From study enrollment until disease progression or loss of clinical benefit (up to approximately 3-5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response as determined by the Investigator according to RECIST v1.1</measure>
    <time_frame>From the date of the first occurrence of a documented objective response to first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) as determined by the Investigator according to RECIST v1.1</measure>
    <time_frame>From start of the treatment up to first occurrence of progressive disease or death from any cause, whichever occurs first (up to approximately 3-5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) as determined by the Investigator according to RECIST v1.1</measure>
    <time_frame>From start of treatment up to death from any cause (up to approximately 3-5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of AB928 target inhibition in peripheral blood</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 4 Day 1 (4 months) and at the end of treatment (in total approximately 5 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunophenotyping activity in select immune subsets for AB928 and IPI-549 in peripheral blood</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 4 Day 1 (4 months) and at the end of treatment (in total approximately 5 months).</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">214</enrollment>
  <condition>TNBC - Triple-Negative Breast Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Dose Escalation-Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation-Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation-Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion-TNBC-Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose given will be determined from the dose escalation part (Arm A).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion-Ovarian Cancer-Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose given will be determined from the dose escalation part (Arm A).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion-TNBC-Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose given will be determined from the dose escalation part (Arm B). .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion-TNBC-Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose expansion will be determined from the dose escalation part (Arm C).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AB928</intervention_name>
    <description>AB928 is an A2aR and A2bR antagonist for oral use</description>
    <arm_group_label>Dose Escalation-Arm A</arm_group_label>
    <arm_group_label>Dose Escalation-Arm B</arm_group_label>
    <arm_group_label>Dose Escalation-Arm C</arm_group_label>
    <arm_group_label>Dose Expansion-Ovarian Cancer-Arm 2</arm_group_label>
    <arm_group_label>Dose Expansion-TNBC-Arm 1</arm_group_label>
    <arm_group_label>Dose Expansion-TNBC-Arm 3</arm_group_label>
    <arm_group_label>Dose Expansion-TNBC-Arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPI-549</intervention_name>
    <description>IPI-549 is a phosphoinositide-3-kinase-gamma inhibitor for oral use</description>
    <arm_group_label>Dose Escalation-Arm C</arm_group_label>
    <arm_group_label>Dose Expansion-TNBC-Arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated liposomal doxorubicin (PLD)</intervention_name>
    <description>Doxil is an anthracycline topoisomerase II inhibitor that is encapsulated in liposomes for intravenous (IV) use</description>
    <arm_group_label>Dose Escalation-Arm A</arm_group_label>
    <arm_group_label>Dose Escalation-Arm C</arm_group_label>
    <arm_group_label>Dose Expansion-Ovarian Cancer-Arm 2</arm_group_label>
    <arm_group_label>Dose Expansion-TNBC-Arm 1</arm_group_label>
    <arm_group_label>Dose Expansion-TNBC-Arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nanoparticle albumin-bound paclitaxel (NP)</intervention_name>
    <description>NP is a microtubule inhibitor for intravenous (IV) use</description>
    <arm_group_label>Dose Escalation-Arm B</arm_group_label>
    <arm_group_label>Dose Expansion-TNBC-Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Female participants, 18 years or older

          2. Measurable disease per radiographic evaluation

          3. Performance status 0 or 1

          4. Available archival tissue sample (within 2 years) or a fresh tumor biopsy may be
             required

          5. Adequate organ, cardiac, and bone marrow function

          6. Dose escalation

               1. Participants with breast cancer:

                    -  Locally advanced or metastatic triple negative breast cancer (ER-negative,
                       PgR-negative, and HER2-negative according to ASCO/CAP guidelines) with
                       disease progression

                    -  No available alternative or curative therapy

                    -  Participants may have received any number of prior therapies for
                       advanced/recurrent and progressive disease

               2. Participants with ovarian cancer:

                    -  Locally advanced or metastatic ovarian cancer with disease progression

                    -  No available alternative or curative therapy Participants may have received
                       any number of prior therapies for advanced/recurrent and progressive disease

          7. Dose expansion

               1. Participants with breast cancer:

                    -  Locally advanced or metastatic triple negative breast cancer (ER-negative,
                       PgR-negative, and HER2-negative according to ASCO/CAP guidelines)

                    -  Disease progression after no more than 3 prior lines of therapy

               2. Participants with ovarian cancer:

                    -  Locally advanced or metastatic ovarian cancer that is platinum-resistant

                    -  Disease progression after no more than 3 prior lines of therapy

        Exclusion:

          1. Received a live, attenuated vaccine within 4 weeks prior to first study treatment

          2. Prior anticancer treatment including approved agents, systemic radiotherapy, or
             investigational therapy within 4 weeks prior first study treatment

          3. Cancer other than the disease under study within 2 years prior to study entry, except
             for some cancers with a low risk of spreading like non-melanoma skin cancers

          4. Inability to swallow oral medications

          5. Participant is breastfeeding, pregnant, or expects to become pregnant during the study

          6. Active autoimmune disease or documented history of autoimmune disease within 2 years
             prior to first study treatment

          7. History of peptic ulcer or stomach bleeding within 6 months prior to first study
             treatment

          8. Use of drugs contraindicated by the protocol within 4 weeks prior to and during study
             treatment

          9. Prior treatment with drugs that suppress the immune system within 2 weeks prior to
             first study treatment

         10. Presence of metastases in the brain or cancer spreading into the cerebrospinal fluid -
             CSF (leptomeningeal disease)

         11. HIV, Hepatitis B, and C test results negative prior to first study treatment

         12. Major surgery within 4 weeks prior to first study treatment

         13. Participants who have previously received maximum cumulative lifetime anthracycline
             dosage or baseline ejection fraction &lt;50% (on heart echography)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Arcus Biosciences, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical Director</last_name>
    <phone>510-694-6200</phone>
    <email>ClinicalTrialInquiry@arcusbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Scottsdale Healthcare Hospitals dba Honor Health Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ti'tanannia Jones</last_name>
      <phone>833-354-6667</phone>
      <email>titajones@honorhealth.com</email>
    </contact>
    <investigator>
      <last_name>Jasgit Sachdev, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Clinical Research Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85715</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Plezia, PharmD</last_name>
      <phone>520-290-2510</phone>
      <email>admin@acrcresearch.com</email>
    </contact>
    <investigator>
      <last_name>Manuel Modiano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melba Avalos</last_name>
      <phone>310-794-2464</phone>
      <email>MCAvalos@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>John Glaspy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers (Aurora)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bobbie Donnachaidh</last_name>
      <phone>303-418-7600</phone>
      <email>bobbie.donnachaidh@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Sami Diab, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miami Cancer Institute at Baptist Health</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alejandra Vargas</last_name>
      <phone>786-596-2000</phone>
      <email>alejandrata@baptisthealth.net</email>
    </contact>
    <investigator>
      <last_name>Ana Sandoval Leon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology, PA</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Lovanni</last_name>
      <phone>240-826-2115</phone>
      <email>Linda.Iovanni@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>John Wallmark, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HealthPartners Institute Cancer Care Center</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Hoiness</last_name>
      <phone>651-254-3391</phone>
      <email>Jason.k.hoiness@healthpartners.com</email>
    </contact>
    <investigator>
      <last_name>Arkadiusz Dudek, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khin Win</last_name>
      <phone>702-419-5550</phone>
      <email>cccn.referrals@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Fadi Braiteh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolina BioOncology Institute</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Bodziony</last_name>
      <phone>980-441-1029</phone>
      <email>dbodziony@carolinabiooncology.org</email>
    </contact>
    <investigator>
      <last_name>John Powderly, II, MD, CPI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Willamette Valley Cancer Institute and Research Center</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roosevelt Anderson</last_name>
      <phone>541-683-5001</phone>
      <email>roosevelt.anderson@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Charles Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A. - Austin (Midtown)</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Owens</last_name>
      <phone>512-421-4143</phone>
      <email>michelle.owens@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Jason Melear, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A. - Baylor Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Lopez</last_name>
      <phone>214-370-1846</phone>
      <email>rita.lopez2@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Carlos Becerra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A. - Fort Worth Cancer Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nori Sullivan</last_name>
      <phone>817-413-1760</phone>
      <email>Nori.Sullivan@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Stephen Richey, MD,MPH, FACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A. - San Antonio Northeast</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martha Ochoa</last_name>
      <phone>210-424-2610</phone>
      <email>martha.ochoa@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Sharon Wilks, MD, FACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A. - San Antonio Medical Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice Bock</last_name>
      <phone>210-595-5300</phone>
      <email>alice.bock@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Sharon Wilks, MD, FACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A. - Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Poe</last_name>
      <phone>903-579-9869</phone>
      <email>Karen.Poe@USOncology.com</email>
    </contact>
    <investigator>
      <last_name>Donald Richards, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paige White</last_name>
      <phone>703-280-5390</phone>
      <email>paige.white@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Neelima Denduluri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendi Gobhardt</last_name>
      <phone>757-213-5813</phone>
      <email>Wendi.Gobhardt@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Paul Conkling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Associates dba Summit Cancer Centers</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Chaudry</last_name>
      <phone>509-462-2273</phone>
      <email>chaudhrym@nwrm.com</email>
    </contact>
    <investigator>
      <last_name>Arvind Chaudry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MultiCare Regional Cancer Center</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Wahinekapu</last_name>
      <phone>910-988-9548</phone>
      <email>dwahinekapu@multicare.org</email>
    </contact>
    <investigator>
      <last_name>Nehal Masood, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chris O'Brien Lifehouse</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Kinghorn Cancer Centre</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorna Flanagan</last_name>
      <phone>61 2 9355 5735</phone>
      <email>lorna.flanagan@svha.org.au</email>
    </contact>
    <investigator>
      <last_name>Amy Prawira, MBBS BMedSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. George Private Hospital</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pan Shu</last_name>
      <phone>61 2 8594 5785</phone>
      <email>pans@ramsayhealth.com.au</email>
    </contact>
    <investigator>
      <last_name>Paul de Souza, BScMed, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Macquarie University</name>
      <address>
        <city>Macquarie</city>
        <state>New South Wales</state>
        <zip>2109</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luke Garcia</last_name>
      <phone>61 2 9812 3553</phone>
      <email>luke.garcia@mq.edu.au</email>
    </contact>
    <investigator>
      <last_name>Dhanusha Sabanthan, BSc(Med) MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pindara Private Hospital</name>
      <address>
        <city>Benowa</city>
        <state>Queensland</state>
        <zip>4217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew McFadzen</last_name>
      <phone>61 7 5588 9888</phone>
      <email>McFadzenA@ramsayhealth.com.au</email>
    </contact>
    <investigator>
      <last_name>Marco Matos, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peninsula &amp; South Eastern Haematology and Oncology Group</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Joost</last_name>
      <phone>61 3 9781 5244</phone>
      <email>aj@paso.com.au</email>
    </contact>
    <investigator>
      <last_name>Vinod Ganju, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cabrini Hospital</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Groom</last_name>
      <phone>61 3 9508 3413</phone>
      <email>MGroom@cabrini.com.au</email>
    </contact>
    <investigator>
      <last_name>Gary Richardson, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>New Zealand</country>
  </removed_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 15, 2018</study_first_submitted>
  <study_first_submitted_qc>October 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2018</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Triple Negative Breast Cancer</keyword>
  <keyword>TNBC</keyword>
  <keyword>Ovarian Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

